WO2000075623A1 - Sample processing device - Google Patents

Sample processing device Download PDF

Info

Publication number
WO2000075623A1
WO2000075623A1 PCT/GB2000/002211 GB0002211W WO0075623A1 WO 2000075623 A1 WO2000075623 A1 WO 2000075623A1 GB 0002211 W GB0002211 W GB 0002211W WO 0075623 A1 WO0075623 A1 WO 0075623A1
Authority
WO
WIPO (PCT)
Prior art keywords
solid phase
liquid
syringe
piston
cartridge
Prior art date
Application number
PCT/GB2000/002211
Other languages
French (fr)
Inventor
Matthew John Baker
Original Assignee
Dna Research Innovations Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dna Research Innovations Limited filed Critical Dna Research Innovations Limited
Priority to AU52363/00A priority Critical patent/AU778440B2/en
Priority to EP00937072A priority patent/EP1183514A1/en
Priority to CA002375449A priority patent/CA2375449A1/en
Priority to JP2001501851A priority patent/JP2003501644A/en
Publication of WO2000075623A1 publication Critical patent/WO2000075623A1/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00Sampling; Preparing specimens for investigation
    • G01N1/28Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40Concentrating samples
    • G01N1/405Concentrating samples by adsorption or absorption

Definitions

  • the present invention relates to a sample processing device and in particular to a sample processing device that can purify biomolecules from crude starting materials such as blood, tissue, plants, microbes, agricultural, food etc.
  • the system can also be used to purify or manipulate any biomolecule or compound from aqueous or non- aqueous samples in a fully automated or manual mode.
  • Clogging of columns or cartridges may be due to frits (a thick, rigid, porous disc/membrane or plug) with small pore sizes or the small size of standard solid phase particles (usually less than 200 microns in diameter) and/or close packing of stationary solid phase material (dependant on size and shape and compressibility).
  • frits a thick, rigid, porous disc/membrane or plug
  • small pore sizes or the small size of standard solid phase particles usually less than 200 microns in diameter
  • close packing of stationary solid phase material dependant on size and shape and compressibility
  • equipment for extracting a material from a liquid mixture containing the material which equipment comprises a container containing a solid phase able to adsorb the material to be extracted and a reversible suction means adapted to apply suction to the solid phase to draw up the liquid mixture over the solid phase and which is able to be reversed so as to pass the liquid back over the solid phase.
  • the reversible suction means can be in the form of a syringe and the solid phase is contained within the syringe below the piston so that when the nozzle of the syringe is placed in the liquid mixture and the piston is withdrawn liquid is drawn up over the solid phase and when the piston is depressed the liquid is passed back over the solid phase.
  • the container containing the solid phase can be attached to the nozzle of a syringe.
  • the reversible suction means comprises a pipette and there is a plug of the solid phase contained within the pipette tip.
  • the novel design allows almost any starting material to be used without clogging the automated extraction system and in a closed environment reducing the risks of contamination to the operator, instrument or to adjacent sample tubes.
  • the design allows the use of existing solid phase extraction methods used in chromatography as well as novel reagents and materials described below.
  • the invention is especially suitable for extracting large macromolecules such as nucleic acids (DNA and RNA) that tend to block or clog existing devices.
  • DNA and RNA nucleic acids
  • the syringe or pumping device with sucking and blowing action can be used in conjunction with a specially modified chromatography cartridge that resists clogging.
  • a biological sample e.g. animal or plant tissue, blood, cells, hair, faeces, agricultural, water, food etc. is homogenised to release the nucleic acids and then passed through a solid phase material to capture the nucleic acids, nuclei or nucleated cells.
  • the cellular debris or contaminants pass up and down to waste leaving the nucleic acids immobilised on the solid phase support.
  • the solid-phase material can be used to remove unwanted cellular debris leaving the DNA or biomolecule in solution.
  • the material to be extracted can be passed up and down the solid phase using the pumping action of the syringe or peristaltic pump. Any type of solid phase can be used since the cartridges are designed to be interchangeable for a wide variety of solid phase extractions.
  • the system will allow homogenisation of samples by introducing a shredding device in the primary cartridge.
  • An enrichment step is often used to remove initial debris and this can be performed using flocculating agents such as cellulose, diatomaceous earth, silica gel, dextrans, PEG or any substance that promotes rapid flocculation and sedimentation of debris or contaminants without requiring centrifugation.
  • flocculating agents such as cellulose, diatomaceous earth, silica gel, dextrans, PEG or any substance that promotes rapid flocculation and sedimentation of debris or contaminants without requiring centrifugation.
  • the instrument of the invention can be designed to handle single or multiple rows of standard syringes (disposable or non-disposable) of different sizes e.g up to 100ml .
  • a single disposable unit with 4, 8, 12, 24 or 96 channels can also be used in conjunction with a pumping system. Thus it is able to dispense large or small volumes in an 8 by 12 tube array.
  • a feature of the instrument of the invention is that the final purified product can be presented in a microtitre plate format of 8 x 12 tubes or as single tubes regardless of the starting volumes of samples. Therefore a great many large samples of blood e.g. 5ml, can be processed for the extraction of DNA simultaneously and then concentrated down to small 1 ml tubes.
  • the disposable cartridge By using sucking and blowing rather than flow-through of reagents and samples, the disposable cartridge retains the sample completely, preventing contamination of any interfaces with the instrument such as tubes, valves and ports of the disposable cartridge. This also minimises the risk to the operator as the disposable item can be automatically discarded.
  • a whole microtitre plate can be processed containing small samples e.g. 1ml buccal cell scrapes, using smaller syringes or pumping devices.
  • a syringe or multi-channel disposable cartridge system is able to operate in X, Y and Z dimensions and can accommodate any pitch changes necessary to handle different sample volumes.
  • the purified analyte may be transferred automatically to a UV/visible spectrophotometer or fluorescent photometer to estimate analyte concentration and purity.
  • UV spectrophotometers require a relatively large sample to analyse in a silica quartz cuvette.
  • the amount of analyte is often in tiny volumes or low concentration. This results in either sacrificing the whole sample or diluting into a bigger volumes which then may make detection very difficult.
  • a disposable probe that dips into the sample the solution can be measured at full strength and without wastage.
  • the instrument design allows incorporation of electrodes or metal meshes or conductive plastic meshes that can be made positively charged to bind nucleic acids from crude extracts. The positive charge can then be turned off or reversed to release the purified nucleic acids.
  • the pumping effect of the instrument allows rapid mixing increasing the contact of the target molecules.
  • porous plastic beads with a diameter of 150microns or greater with very large pores e.g. 1 to 20 microns, made from polypropylene, polyethylene or any polymer with a natural affinity for specific biomolecules.
  • Other materials can also be used; cellulose, agarose, glass, silica or any suitable material that may be derivatised to extract a target analyte.
  • the solid-phase may be derivatised with imidazole groups, amine, carboxy or any group with an affinity for nucleic acids or the target molecule/compound.
  • the beads may be used with a frit or membrane or a single hole or multi hole mesh depending on the flow rates required.
  • the beads may be composed of material that has an inherent affinity of biomolecules such as poly vinyl pyridine that is positively charged at pH 4 and will bind DNA and elute it at pH 8.
  • Any polymeric compound can be converted into beads or particles or surfaces for binding and may include groups such as pyrazole, pyrole, pyrroldine, indole, pyrimidine, nucleic acid bases, imidazole, imines, amines, lysines or any groups that have a pKa in the range of 3 to 12.
  • a pKa of 5 to 8 is employed to maintain physiological conditions if biological samples are being processed and can thus be manipulated by pH to turn a positive charge on or off.
  • the beads may also be converted for chelation of biomolecules such as iminodiacetic acid beads bound with ferric ions at pH 3 to bind nucleic acids. Raising the pH removes the purified nucleic acids. Calcium, Magnesium or Ammonium ions can also be used to chelate biomolecules.
  • the beads can be held stationary using frits or membranes as long as the pore diameters are large enough to allow easy passage of crude matter. In most cases the frits or membranes require relatively large holes (pin holes) not found in conventional materials. Alternatively the beads may be held in place by narrowing the inlet and outlet of the cartridge removing the need for frits or they may be held in place by a mesh incorporated into the design of the cartridge.
  • the larger beads can be allowed to move inside the column by having space inside the cartridge. This helps with mixing and reduces clogging.
  • the beads can be added to the crude mixture as a suspension and then trapped in a cartridge when the target molecules are bound thus achieving separation.
  • Non-porous magnetic (paramagnetic) beads are less than 50microns but are difficult to handle when extracting genomic or microbial DNA. Large porous magnetic beads may lead to internal entrapment of contaminants as the macromolecule such as DNA bind to the outer surface of the beads, these contaminants are only released when the DNA is eluted contaminating the final preparation.
  • Porous membranes or frits can be modified by adding larger holes and used in spaced stacks or individually to bind biomolecules from crude extracts, e.g. blood.
  • Existing membranes or frits block instantly when encountering crude extracts or high molecular weight DNA.
  • the invention describes the use of a unique pore size modification that allows the treatment of crude materials in large or small volumes that is also amenable to automation.
  • a small or large device can be constructed based on the same design.
  • the small device relies on a standard plastic pipette tip that incorporates a single porous plug, wadding, or frit with a pore size that prevents blocking.
  • This can be used with a conventional pipette or syringe in a manual mode or in a fully automated pipetting station.
  • they can be incorporated into Deep Well plates, Microtitre plates or PCR tubes and used with centrifugation or vacuum manifolds.
  • the frits may also be incorporated directly inside a syringe 1ml to 60ml instead of an extra cartridge.
  • the plug or frit may be derivatised to bind DNA or any biomolecule.
  • additional plugs or frits can be added in stacks separated by a small air barrier to avoid blocking and maintain exposed surfaces for binding the target compound.
  • the material for the membrane or frit may be porous polyethylene with a primary pore size of 1 to 200 microns or preferably 20 microns , or any porous plastic, porous glass, cellulose with pores large enough to allow passage of crude matter. E.g. 20 microns or larger.
  • the material may have small pore sizes that will enable binding of target molecule, but they must also possess larger holes e.g. 0.1 mm or greater to avoid blocking. This larger hole may be at the edges or in the middle or part of a cut away section.
  • frits can be incorporated in a single cartridge to perform sequential or discrete separations, e.g. one frit separates the nuclei and another derivatised with silica or imidazole groups purifies the DNA further up the cartridge or in a separate device.
  • the initial capture of DNA, RNA, or other biomolecules can be performed, then the analyte is washed off and carried up the syringe and precipitated with a compound such as PEG, alcohol, ammonium or sodium sulphate. The precipitated compound may then be re-captured allowing the soluble contaminants to pass to waste.
  • a syringe based system can be used to filter a crude sample by incorporating a filter membrane or plug at the tip of the cartridge or pipette tip. The debris is left behind as the liquid is sucked up through the plug. After rinsing the plug free of debris the clarified solution is dispensed into a new tube.
  • This technique can be assisted by using a filter-aid such as silica gel, titanium oxide, fibrous cellulose etc.
  • a filter-aid is added to flocculate and compact the debris at the bottom of the tube leaving the target molecule in the supernatant ready for processing or purification.
  • the filter-aid may be soluble, possess temperature dependant solubility or be insoluble.
  • a by-pass channel can be introduced that allows larger particles or debris to pass up and down without clogging the cartridge.
  • a bypass channel may be created as small tube that by passes the solid phase or a porous material with large pores e.g. 20 microns or greater, that surrounds the solid phase.
  • solid-phase beads are employed for conventional extractions. For example, less than 100 micron glass, then the solid -phase can be allowed to move internally so clogging is avoided.
  • the introduction of ridges, spirals or obstructions inside the cartridge helps prevent the solid-phase moving in bulk maintaining good mixing and separation of solid-phase. If the solid-phase particles are large enough of sufficiently dense, e.g. 200 micron glass, a mini-fluidised bed can be generated.
  • Clogging of cartridges may also be avoided by the pre-addition of a mobile solid- phase to capture the target molecule.
  • the loose solid-phase or paramagnetic beads are added as a suspension and the contaminants are washed away leaving the immobilised target compound ready for further purification in a cartridge or analysis.
  • Any type of solid phase can be added with a preference for material that will sediment quickly or be flocculated by filter aids to avoid centrifugation or are paramagnetic.
  • the instrument and disposable cartridge or tip system has a variety of applications including molecular biology such as affinity purification of cell antibodies, enzymes and other proteins, purging of mixtures to remove unwanted compounds, combinatorial chemistry, ion exchange purification, hydrophobic chromatography, enzyme assays using immobilised antibodies, nucleic acids or antigens, enzyme catalysis on solid phase supports, food screening for pathogens, genomic DNA, toxins, allergens, etc., clinical sample processing for pathogenic organisms, mixing adjuvants for immunisation and making stable emulsions, pipetting larger volumes, removal of lipoproteins for cholesterol assays, detecting or concentrating pathogens in milk, food or water.
  • molecular biology such as affinity purification of cell antibodies, enzymes and other proteins, purging of mixtures to remove unwanted compounds, combinatorial chemistry, ion exchange purification, hydrophobic chromatography, enzyme assays using immobilised antibodies, nucleic acids or antigens, enzyme catalysis on solid phase supports, food screening for
  • Fig. 1 illustrates with the solid phase inside a syringe
  • Fig.2 shows the use of a cartridge
  • Fig. 3 shows a pipette
  • Figs. 4, 5 and 6 show alternative cartridges
  • Figs. 7, 8 and 9 show different disc arrangements.
  • a syringe (1) having a moveable piston (2) has an adsorbent solid phase (3) held within it.
  • the nozzle (4) is placed within the liquid from which material is to be separated and the piston withdrawn to suck up the liquid through (3).
  • the piston is depressed the liquid is forced back over (3) and this process can be repeated if desired so that there is better adsorption of material from the liquid.
  • the syringe (5) with a piston (6) has nozzle (7) placed in cartridge (8) containing a solid adsorbent and the cartridge (8) has its inlet (9) placed in the liquid from which material is to be separated.
  • the piston (6) is withdrawn the liquid is drawn up through the cartridge and material is adsorbed, when the piston is depressed the liquid is forced back over the adsorbent in the cartridge so that there is better adsorption of material from the liquid.
  • the adsorbent material (10) can be in the form of frits or beads and can fill the cartridge.
  • a by-pass channel (11) round the outside of the solid adsorbent so that larger particles can pass up and down without clogging.
  • each disc consists of an adsorbent membrane
  • the discs can have large pores as illustrated in fig. 7 and can have cut away sections as shown in fig. 8 to prevent blocking.
  • the discs can be stacked on top the other and can have a raised lip (14) as shown in fig. 9 so that the discs are only in contact through this lip.
  • a pipette (15) has an aerosol plug (16) to prevent contamination and contains a plug (16) of adsorbent material such as a porous plastic material as shown.
  • adsorbent material such as a porous plastic material as shown.
  • the tip of the pipette (17) is placed in the liquid and liquid is sucked up over the plug (16), by blowing down the pipette the liquid is forced back over the plug (16) so that there is better adsorption of material from the liquid.
  • the adsorbed material can be removed from the solid phase by conventional elution methods.
  • polystyrene porous carboxylated beads 200 - 500 microns or 16 - 50 mesh size
  • plastic mesh with pore sizes of about 100 microns.
  • the dilution buffer can be any hypotonic solution that causes lysis of the red blood cell fraction, but maintains the integrity of nuclei, white blood cells or chromatin.
  • the nuclei became immobilised on the beads and the lysed blood was taken to waste. Direct elution of the nuclear DNA was achieved using hot water.
  • the eluate from the first cartridge was then further processed using another cartridge containing a solid-phase with poly imidazole groups.
  • To collect the white blood cell fraction the same solution is made isotonic with saline and the cells were captured in a similar manner.
  • polystyrene porous carboxylated beads 200 - 500 microns or 16 - 50 mesh size
  • polystyrene porous carboxylated beads 200 - 500 microns or 16 - 50 mesh size
  • agarose was treated with carbonyldiimidazole in anhydrous organic solvent and then left in water at pH 3 to maintain the imidazole groups.
  • the derivatised agarose was placed in a cartridge and the supernatant from a plasmid alkaline lysis preparation was sucked up and down immobilising the plasmid DNA on the beads at pH 5. After washing, the plasmid DNA was eluted with lOmM Tris HC1, pH 9.
  • the frit and nuclei was then washed to remove residual proteins using deionised water or chaotropes or alcohols or detergents such SDS or Tween 20 or combinations or lactic and salicylic acids or their salts, or poly phosphates or per chlorates and either eluted off using hot water or alkaline solutions of detergents or further purified inside the cartridge using chaotropic agents or proteases.
  • deionised water or chaotropes or alcohols or detergents such SDS or Tween 20 or combinations or lactic and salicylic acids or their salts, or poly phosphates or per chlorates
  • a plug of porous polyethylene was derivatised with imidazole groups and inserted into the tip of a standard 1ml pipette tip.
  • a further non derivatised plug was inserted at the top to act as an aerosol and liquid barrier to prevent contamination of the pipette.
  • a buccal scrape was taken and mixed with 0.2M guanidine isothiocyanate, 3% Tween 20, Proteinase K and 50mM MES pH5 at 30°C for 15 minutes. The mixture was then sucked up and down the tip several times allowing the DNA to bind to the derivatised plug.
  • the plug was washed with ImM MES pH5 and then the DNA eluted with lOmM Tris. HCI pH9. The same protocol was repeated using 0.01% to 10% SDS with or without salts and buffers. Fast degradation of the buccal cells can also be achieved using salicylic acid, lactic acid, or MgCl at concentrations of 0.05 to 5M. Combinations of the above salts and reagents can also be used.
  • Example 6 1 gram of carboxylated polystyrene beads with a diameter of about 60 microns or 200 to 400 mesh was suspended in a hypotonic solution of ammonium bicarbonate 1 OmM with 0.1 % Tween 20 pH9. A five fold excess of this suspension was added to a 5ml blood sample and mixed once. The beads captured the nuclei and sedimented. After several washes with water, the DNA was eluted with hot water. To concentrate the DNA the equipment of fig. 2 was used with the packing of fig. 6 and the DNA was captured on a porous disc in the cartridge and subsequently eluted off in a small volume and analysed using PCR or Restriction Digestion
  • Example 7 Removal and purification of human IgG from serum An agarose gel coupled to Protein A was placed in the cartridge of fig. 2 and washed with phosphate buffered saline. A solution containing human IgG in serum was sucked up and down the solid phase until all the IgG was bound. After washing the solid phase with PBS, the IgG was eluted with 0.1 M glycine, 0.1 5M NaCl, pH2.8 and immediately neutralised with Tris. HCI.
  • Example 8 Purification and isolation of specific white blood cell types from whole blood
  • Non-porous glass particles of 175 microns were coupled to CD4 monoclonal antibodies and the solid phase placed in a cartridge as in Example 4 with 80micron frits. A diluted solution of Buffy Coat was sucked slowly up and down through the glass beads immobilising the T cell sub-population which could be released.
  • Example 9 Recombinant protein purification An agarose gel containing Iminodiacetic acid-Nickel ion groups was packed into a cartridge as in Example 4.
  • a bacterial lysate containing a recombinant protein possessing a 6 histidine tail was sucked up and down the cartridge and the protein was bound to the co-ordinated nickel. Release of the protein was effected by eluting with 0.5M Imidazole pH 6.
  • a cartridge as in fig. 2 was packed with 60 micron silica and a sample of serum diluted 5 times with 6M guanidine isothiocyanate, 0.1 % Tween 20, 20mM EDTA, lOOmM Tris. HCI pH6 was sucked up and down through the solid phase. After washing the solid phase with isopropanol and drying the RNA was eluted using water at 60C.
  • a cartridge as in fig. 2 was packed with 60 micron silica and a sample of a PCR reaction diluted 5 times with 6M guanidine isothiocyanate, 0. 1 % Tween 20, 20mM
  • Fresh liver was homogenised in a mixture of 50% Phenol containing 6M Guanidine isothiocyanate, lOmM DTT, 0.1 M Sodium Acetate pH 4. Chloroform was added to separate the phases and the top layer containing the RNA was sucked up and down through a cartridge of fig. 2 containing 60micron silica. The silica was washed with alcohol, air dried and the RNA eluted with hot water ready for processing.
  • a cartridge was packed with COOH polystyrene beads coupled to oligo dT 30 5'
  • a sample of white blood cells prepared earlier in a cartridge were treated with an excess of 1% SDS, 0.5M LiCl, lOmM DTT, lOmM Tris. HCI pH 7.5 and sucked up and down through the affinity resin several times to shear the DNA and bind the mRNA. The resin was then washed in 0.1 M LiCl and air dried. Elution of mRNA was performed by hot water.
  • Example 4 that was coupled to oligo dT30 and used for binding less than 5 micrograms ofmRNA.
  • Streptavidin was immobilised onto porous frits by mixing the protein in 0.1 M sodium phosphate buffer with 0.01% glutaldehyde pH7 as in example 4. Biotinylated primers used to generate a PCR product were then isolated on the immobilised streptavidin. The PCR product was then made single stranded using heat or 0.1 M NaOH and used for sequencing or probe analysis.
  • Example 15 Use of electrodes, static charge, induction, electrophoresis to isolate DNA or RNA

Landscapes

  • Physics & Mathematics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Sampling And Sample Adjustment (AREA)

Abstract

A method for extracting biomolecules such as DNA from a liquid mixture comprises passing the liquid up and down through a solid phase incorporating an adsorbent for the biomolecule.

Description

Sample Processing Device
The present invention relates to a sample processing device and in particular to a sample processing device that can purify biomolecules from crude starting materials such as blood, tissue, plants, microbes, agricultural, food etc. The system can also be used to purify or manipulate any biomolecule or compound from aqueous or non- aqueous samples in a fully automated or manual mode.
Conventional chromatography columns are not suitable for direct extraction of biomolecules from crude starting materials containing particulate matter, viscous material, or cellular debris. This is due to the type of solid phase employed and the design of the column or cartridge that are prone to blocking or clogging. This also applies to mini-chromatography columns processed using a vacuum or centrifugation to pass the liquid over the solid supports. This clogging problem is exacerbated when attempting to extract high molecular weight DNA without shearing it into small fragments. Clogging of columns or cartridges may be due to frits (a thick, rigid, porous disc/membrane or plug) with small pore sizes or the small size of standard solid phase particles (usually less than 200 microns in diameter) and/or close packing of stationary solid phase material (dependant on size and shape and compressibility).
We have now devised equipment and a method which reduces these problems.
According to the invention there is provided equipment for extracting a material from a liquid mixture containing the material which equipment comprises a container containing a solid phase able to adsorb the material to be extracted and a reversible suction means adapted to apply suction to the solid phase to draw up the liquid mixture over the solid phase and which is able to be reversed so as to pass the liquid back over the solid phase. The reversible suction means can be in the form of a syringe and the solid phase is contained within the syringe below the piston so that when the nozzle of the syringe is placed in the liquid mixture and the piston is withdrawn liquid is drawn up over the solid phase and when the piston is depressed the liquid is passed back over the solid phase.
Alternatively the container containing the solid phase can be attached to the nozzle of a syringe.
In another embodiment of the invention the reversible suction means comprises a pipette and there is a plug of the solid phase contained within the pipette tip.
It is a feature of the invention that the novel design allows almost any starting material to be used without clogging the automated extraction system and in a closed environment reducing the risks of contamination to the operator, instrument or to adjacent sample tubes.
The design allows the use of existing solid phase extraction methods used in chromatography as well as novel reagents and materials described below.
The invention is especially suitable for extracting large macromolecules such as nucleic acids (DNA and RNA) that tend to block or clog existing devices.
The syringe or pumping device with sucking and blowing action can be used in conjunction with a specially modified chromatography cartridge that resists clogging. For example, a biological sample e.g. animal or plant tissue, blood, cells, hair, faeces, agricultural, water, food etc. is homogenised to release the nucleic acids and then passed through a solid phase material to capture the nucleic acids, nuclei or nucleated cells. The cellular debris or contaminants pass up and down to waste leaving the nucleic acids immobilised on the solid phase support. Alternatively, the solid-phase material can be used to remove unwanted cellular debris leaving the DNA or biomolecule in solution.
The material to be extracted can be passed up and down the solid phase using the pumping action of the syringe or peristaltic pump. Any type of solid phase can be used since the cartridges are designed to be interchangeable for a wide variety of solid phase extractions.
Additionally, the system will allow homogenisation of samples by introducing a shredding device in the primary cartridge.
This allows difficult samples, such as plant extracts, animal tissue, faeces, food or other samples requiring maceration to release cellular contents such as proteins or nucleic acids. The target molecules can then be captured on the solid-phase and the homogenisation and purification process is thus completely automated.
An enrichment step is often used to remove initial debris and this can be performed using flocculating agents such as cellulose, diatomaceous earth, silica gel, dextrans, PEG or any substance that promotes rapid flocculation and sedimentation of debris or contaminants without requiring centrifugation.
The instrument of the invention can be designed to handle single or multiple rows of standard syringes (disposable or non-disposable) of different sizes e.g up to 100ml . A single disposable unit with 4, 8, 12, 24 or 96 channels can also be used in conjunction with a pumping system. Thus it is able to dispense large or small volumes in an 8 by 12 tube array.
A feature of the instrument of the invention is that the final purified product can be presented in a microtitre plate format of 8 x 12 tubes or as single tubes regardless of the starting volumes of samples. Therefore a great many large samples of blood e.g. 5ml, can be processed for the extraction of DNA simultaneously and then concentrated down to small 1 ml tubes.
By using sucking and blowing rather than flow-through of reagents and samples, the disposable cartridge retains the sample completely, preventing contamination of any interfaces with the instrument such as tubes, valves and ports of the disposable cartridge. This also minimises the risk to the operator as the disposable item can be automatically discarded.
Alternatively, a whole microtitre plate can be processed containing small samples e.g. 1ml buccal cell scrapes, using smaller syringes or pumping devices.
A syringe or multi-channel disposable cartridge system is able to operate in X, Y and Z dimensions and can accommodate any pitch changes necessary to handle different sample volumes. The purified analyte may be transferred automatically to a UV/visible spectrophotometer or fluorescent photometer to estimate analyte concentration and purity.
Most conventional UV spectrophotometers require a relatively large sample to analyse in a silica quartz cuvette. Unfortunately, in biological samples the amount of analyte is often in tiny volumes or low concentration. This results in either sacrificing the whole sample or diluting into a bigger volumes which then may make detection very difficult. By having a disposable probe that dips into the sample the solution can be measured at full strength and without wastage.
The instrument design allows incorporation of electrodes or metal meshes or conductive plastic meshes that can be made positively charged to bind nucleic acids from crude extracts. The positive charge can then be turned off or reversed to release the purified nucleic acids. The pumping effect of the instrument allows rapid mixing increasing the contact of the target molecules. In one format there could be a mesh, bead or tip incorporated as a plastic disposable that can carry a positive charge by applying a potential difference or induction. As the sample passes across the mesh or membrane the nuclei acids bind and can be released as the charge is reversed or switched off.
Large highly porous or non-porous solid phase beads may be used to avoid clogging and maintain high flow rates. For example; porous plastic beads with a diameter of 150microns or greater with very large pores e.g. 1 to 20 microns, made from polypropylene, polyethylene or any polymer with a natural affinity for specific biomolecules. Other materials can also be used; cellulose, agarose, glass, silica or any suitable material that may be derivatised to extract a target analyte.
The solid-phase may be derivatised with imidazole groups, amine, carboxy or any group with an affinity for nucleic acids or the target molecule/compound. The beads may be used with a frit or membrane or a single hole or multi hole mesh depending on the flow rates required.
The beads may be composed of material that has an inherent affinity of biomolecules such as poly vinyl pyridine that is positively charged at pH 4 and will bind DNA and elute it at pH 8. Any polymeric compound can be converted into beads or particles or surfaces for binding and may include groups such as pyrazole, pyrole, pyrroldine, indole, pyrimidine, nucleic acid bases, imidazole, imines, amines, lysines or any groups that have a pKa in the range of 3 to 12. Preferably a pKa of 5 to 8 is employed to maintain physiological conditions if biological samples are being processed and can thus be manipulated by pH to turn a positive charge on or off.
The beads may also be converted for chelation of biomolecules such as iminodiacetic acid beads bound with ferric ions at pH 3 to bind nucleic acids. Raising the pH removes the purified nucleic acids. Calcium, Magnesium or Ammonium ions can also be used to chelate biomolecules. The beads can be held stationary using frits or membranes as long as the pore diameters are large enough to allow easy passage of crude matter. In most cases the frits or membranes require relatively large holes (pin holes) not found in conventional materials. Alternatively the beads may be held in place by narrowing the inlet and outlet of the cartridge removing the need for frits or they may be held in place by a mesh incorporated into the design of the cartridge.
The larger beads can be allowed to move inside the column by having space inside the cartridge. This helps with mixing and reduces clogging. Alternatively, the beads can be added to the crude mixture as a suspension and then trapped in a cartridge when the target molecules are bound thus achieving separation.
Large diameter beads are also useful for preparing magnetic solid phases which are not prone to aggregation during isolation of large macromolecules such as nucleic acids. Most non-porous magnetic (paramagnetic) beads are less than 50microns but are difficult to handle when extracting genomic or microbial DNA. Large porous magnetic beads may lead to internal entrapment of contaminants as the macromolecule such as DNA bind to the outer surface of the beads, these contaminants are only released when the DNA is eluted contaminating the final preparation.
Porous membranes or frits can be modified by adding larger holes and used in spaced stacks or individually to bind biomolecules from crude extracts, e.g. blood. Existing membranes or frits block instantly when encountering crude extracts or high molecular weight DNA. The invention describes the use of a unique pore size modification that allows the treatment of crude materials in large or small volumes that is also amenable to automation.
For DNA extraction from blood, a small or large device can be constructed based on the same design. The small device relies on a standard plastic pipette tip that incorporates a single porous plug, wadding, or frit with a pore size that prevents blocking. This can be used with a conventional pipette or syringe in a manual mode or in a fully automated pipetting station. Alternatively, they can be incorporated into Deep Well plates, Microtitre plates or PCR tubes and used with centrifugation or vacuum manifolds. The frits may also be incorporated directly inside a syringe 1ml to 60ml instead of an extra cartridge.
The plug or frit may be derivatised to bind DNA or any biomolecule. For larger extractions additional plugs or frits can be added in stacks separated by a small air barrier to avoid blocking and maintain exposed surfaces for binding the target compound.
The material for the membrane or frit may be porous polyethylene with a primary pore size of 1 to 200 microns or preferably 20 microns , or any porous plastic, porous glass, cellulose with pores large enough to allow passage of crude matter. E.g. 20 microns or larger. The material may have small pore sizes that will enable binding of target molecule, but they must also possess larger holes e.g. 0.1 mm or greater to avoid blocking. This larger hole may be at the edges or in the middle or part of a cut away section.
A variety of frits can be incorporated in a single cartridge to perform sequential or discrete separations, e.g. one frit separates the nuclei and another derivatised with silica or imidazole groups purifies the DNA further up the cartridge or in a separate device. Alternatively, the initial capture of DNA, RNA, or other biomolecules can be performed, then the analyte is washed off and carried up the syringe and precipitated with a compound such as PEG, alcohol, ammonium or sodium sulphate. The precipitated compound may then be re-captured allowing the soluble contaminants to pass to waste. A syringe based system can be used to filter a crude sample by incorporating a filter membrane or plug at the tip of the cartridge or pipette tip. The debris is left behind as the liquid is sucked up through the plug. After rinsing the plug free of debris the clarified solution is dispensed into a new tube.
This technique can be assisted by using a filter-aid such as silica gel, titanium oxide, fibrous cellulose etc.
Following homogenisation, a filter-aid is added to flocculate and compact the debris at the bottom of the tube leaving the target molecule in the supernatant ready for processing or purification.
The filter-aid may be soluble, possess temperature dependant solubility or be insoluble.
If smaller solid-phase beads are employed for conventional extractions. For example, less than 100 micron glass, then a by-pass channel can be introduced that allows larger particles or debris to pass up and down without clogging the cartridge. A bypass channel may be created as small tube that by passes the solid phase or a porous material with large pores e.g. 20 microns or greater, that surrounds the solid phase.
For very pure DNA further purifications can be performed with another cartridge inline to allow the use of the salting out technique. This salting out technique can be used in conjunction with alcoholic precipitation and capture of the insoluble nucleic acids.
If smaller solid-phase beads are employed for conventional extractions. For example, less than 100 micron glass, then the solid -phase can be allowed to move internally so clogging is avoided. The introduction of ridges, spirals or obstructions inside the cartridge helps prevent the solid-phase moving in bulk maintaining good mixing and separation of solid-phase. If the solid-phase particles are large enough of sufficiently dense, e.g. 200 micron glass, a mini-fluidised bed can be generated.
Clogging of cartridges may also be avoided by the pre-addition of a mobile solid- phase to capture the target molecule. The loose solid-phase or paramagnetic beads are added as a suspension and the contaminants are washed away leaving the immobilised target compound ready for further purification in a cartridge or analysis. Any type of solid phase can be added with a preference for material that will sediment quickly or be flocculated by filter aids to avoid centrifugation or are paramagnetic.
The instrument and disposable cartridge or tip system has a variety of applications including molecular biology such as affinity purification of cell antibodies, enzymes and other proteins, purging of mixtures to remove unwanted compounds, combinatorial chemistry, ion exchange purification, hydrophobic chromatography, enzyme assays using immobilised antibodies, nucleic acids or antigens, enzyme catalysis on solid phase supports, food screening for pathogens, genomic DNA, toxins, allergens, etc., clinical sample processing for pathogenic organisms, mixing adjuvants for immunisation and making stable emulsions, pipetting larger volumes, removal of lipoproteins for cholesterol assays, detecting or concentrating pathogens in milk, food or water.
A device of the invention is described in the accompanying drawings in which:-
Fig. 1 illustrates with the solid phase inside a syringe
Fig.2 shows the use of a cartridge
Fig. 3 shows a pipette
Figs. 4, 5 and 6 show alternative cartridges and
Figs. 7, 8 and 9 show different disc arrangements. Referring to fig. 1 a syringe (1) having a moveable piston (2) has an adsorbent solid phase (3) held within it. In use the nozzle (4) is placed within the liquid from which material is to be separated and the piston withdrawn to suck up the liquid through (3). When the piston is depressed the liquid is forced back over (3) and this process can be repeated if desired so that there is better adsorption of material from the liquid.
Referring to fig. 2 the syringe (5) with a piston (6) has nozzle (7) placed in cartridge (8) containing a solid adsorbent and the cartridge (8) has its inlet (9) placed in the liquid from which material is to be separated. When the piston (6) is withdrawn the liquid is drawn up through the cartridge and material is adsorbed, when the piston is depressed the liquid is forced back over the adsorbent in the cartridge so that there is better adsorption of material from the liquid.
Referring to fig. 4 the adsorbent material (10) can be in the form of frits or beads and can fill the cartridge.
Referring to fig. 5 there can be a by-pass channel (11) round the outside of the solid adsorbent so that larger particles can pass up and down without clogging.
Referring to fig. 6 there are discs (12) positioned within the cartridge and each disc consists of an adsorbent membrane, the discs can have large pores as illustrated in fig. 7 and can have cut away sections as shown in fig. 8 to prevent blocking. The discs can be stacked on top the other and can have a raised lip (14) as shown in fig. 9 so that the discs are only in contact through this lip.
Referring to fig. 3 a pipette (15) has an aerosol plug (16) to prevent contamination and contains a plug (16) of adsorbent material such as a porous plastic material as shown. In us the tip of the pipette (17) is placed in the liquid and liquid is sucked up over the plug (16), by blowing down the pipette the liquid is forced back over the plug (16) so that there is better adsorption of material from the liquid. The adsorbed material can be removed from the solid phase by conventional elution methods.
The invention is described in the following examples in which the isolated or eluted products were identified using conventional laboratory analysis methods.
Example 1
Using the equipment of fig. 2 polystyrene porous carboxylated beads (200 - 500 microns or 16 - 50 mesh size) were loaded into a chromatography cartridge and held in place with plastic mesh with pore sizes of about 100 microns.
Whole blood was diluted 10 times with lOmM Ammonium Bicarbonate, lOmM Ammonium Carbonate and 0.1 % Tween 20 pH9 and sucked up and down the cartridge with a syringe and passed back through the cartridge. The dilution buffer can be any hypotonic solution that causes lysis of the red blood cell fraction, but maintains the integrity of nuclei, white blood cells or chromatin. The nuclei became immobilised on the beads and the lysed blood was taken to waste. Direct elution of the nuclear DNA was achieved using hot water. To obtain greater purity DNA, the eluate from the first cartridge was then further processed using another cartridge containing a solid-phase with poly imidazole groups. To collect the white blood cell fraction, the same solution is made isotonic with saline and the cells were captured in a similar manner.
Example 2
Using the equipment of fig. 3 polystyrene porous carboxylated beads (200 - 500 microns or 16 - 50 mesh size) were loaded into a 1 ml pipette tip.
Whole blood was diluted 10 times with lOmM Ammonium Bicarbonate and 0.01% Tween 20 pH9 and sucked up and down the tip of the pipette. The nuclei became immobilised on the beads and the lysed blood was removed to waste. Direct elution of the nuclear DNA was achieved using alkaline detergent solutions and by boiling water. Example 3
Using the equipment of fig. 2 agarose was treated with carbonyldiimidazole in anhydrous organic solvent and then left in water at pH 3 to maintain the imidazole groups. The derivatised agarose was placed in a cartridge and the supernatant from a plasmid alkaline lysis preparation was sucked up and down immobilising the plasmid DNA on the beads at pH 5. After washing, the plasmid DNA was eluted with lOmM Tris HC1, pH 9.
The above was repeated with carboxylated polystyrene and dextrans of various sizes and DNA obtained by elution as above.
Example 4
Extraction of nuclei or DNA from whole blood
Using the equipment of fig. 2 with the packing of fig. 6 whole blood was lysed with 5 volumes of lOmM Ammonium Bicarbonate containing 0.1 %Tween 20 pH9. The lysed blood was passed through several 20micron porous polyethylene frits modified with larger pores of 1 mm in diameter, housed in a plastic cartridge attached to a 2ml syringe and plunger. Each frit was spaced 3mm apart to allow free flow of liquid. The nuclei or white blood cell fraction bound to the frit allowing all the contaminating proteins and lipids to pass through to waste in a single pass or several strokes of the plunger. The frit and nuclei was then washed to remove residual proteins using deionised water or chaotropes or alcohols or detergents such SDS or Tween 20 or combinations or lactic and salicylic acids or their salts, or poly phosphates or per chlorates and either eluted off using hot water or alkaline solutions of detergents or further purified inside the cartridge using chaotropic agents or proteases.
Example 5
Purification of buccal cell DNA Using the equipment of fig. 3 a plug of porous polyethylene was derivatised with imidazole groups and inserted into the tip of a standard 1ml pipette tip. A further non derivatised plug was inserted at the top to act as an aerosol and liquid barrier to prevent contamination of the pipette. A buccal scrape was taken and mixed with 0.2M guanidine isothiocyanate, 3% Tween 20, Proteinase K and 50mM MES pH5 at 30°C for 15 minutes. The mixture was then sucked up and down the tip several times allowing the DNA to bind to the derivatised plug. The plug was washed with ImM MES pH5 and then the DNA eluted with lOmM Tris. HCI pH9. The same protocol was repeated using 0.01% to 10% SDS with or without salts and buffers. Fast degradation of the buccal cells can also be achieved using salicylic acid, lactic acid, or MgCl at concentrations of 0.05 to 5M. Combinations of the above salts and reagents can also be used.
Example 6 1 gram of carboxylated polystyrene beads with a diameter of about 60 microns or 200 to 400 mesh was suspended in a hypotonic solution of ammonium bicarbonate 1 OmM with 0.1 % Tween 20 pH9. A five fold excess of this suspension was added to a 5ml blood sample and mixed once. The beads captured the nuclei and sedimented. After several washes with water, the DNA was eluted with hot water. To concentrate the DNA the equipment of fig. 2 was used with the packing of fig. 6 and the DNA was captured on a porous disc in the cartridge and subsequently eluted off in a small volume and analysed using PCR or Restriction Digestion
Example 7 Removal and purification of human IgG from serum An agarose gel coupled to Protein A was placed in the cartridge of fig. 2 and washed with phosphate buffered saline. A solution containing human IgG in serum was sucked up and down the solid phase until all the IgG was bound. After washing the solid phase with PBS, the IgG was eluted with 0.1 M glycine, 0.1 5M NaCl, pH2.8 and immediately neutralised with Tris. HCI. Example 8 Purification and isolation of specific white blood cell types from whole blood
Non-porous glass particles of 175 microns were coupled to CD4 monoclonal antibodies and the solid phase placed in a cartridge as in Example 4 with 80micron frits. A diluted solution of Buffy Coat was sucked slowly up and down through the glass beads immobilising the T cell sub-population which could be released.
Example 9 Recombinant protein purification An agarose gel containing Iminodiacetic acid-Nickel ion groups was packed into a cartridge as in Example 4.
A bacterial lysate containing a recombinant protein possessing a 6 histidine tail was sucked up and down the cartridge and the protein was bound to the co-ordinated nickel. Release of the protein was effected by eluting with 0.5M Imidazole pH 6.
Example 10 Extraction of HIV RNA from serum
A cartridge as in fig. 2 was packed with 60 micron silica and a sample of serum diluted 5 times with 6M guanidine isothiocyanate, 0.1 % Tween 20, 20mM EDTA, lOOmM Tris. HCI pH6 was sucked up and down through the solid phase. After washing the solid phase with isopropanol and drying the RNA was eluted using water at 60C.
Example 11 Purification of PCR reactions
A cartridge as in fig. 2 was packed with 60 micron silica and a sample of a PCR reaction diluted 5 times with 6M guanidine isothiocyanate, 0. 1 % Tween 20, 20mM
EDTA, lOOmM Tris-HCl pH6 was sucked up through the solid phase. After washing the solid phase with isopropanol and drying the DNA was eluted using water.
Example 12 Extraction of RNA from Liver
Fresh liver was homogenised in a mixture of 50% Phenol containing 6M Guanidine isothiocyanate, lOmM DTT, 0.1 M Sodium Acetate pH 4. Chloroform was added to separate the phases and the top layer containing the RNA was sucked up and down through a cartridge of fig. 2 containing 60micron silica. The silica was washed with alcohol, air dried and the RNA eluted with hot water ready for processing.
Example 13 Isolation of mRNA
A cartridge was packed with COOH polystyrene beads coupled to oligo dT 30 5'
NH2.
A sample of white blood cells prepared earlier in a cartridge were treated with an excess of 1% SDS, 0.5M LiCl, lOmM DTT, lOmM Tris. HCI pH 7.5 and sucked up and down through the affinity resin several times to shear the DNA and bind the mRNA. The resin was then washed in 0.1 M LiCl and air dried. Elution of mRNA was performed by hot water.
The above experiment was repeated with a carboxylated plastic porous frit as in
Example 4 that was coupled to oligo dT30 and used for binding less than 5 micrograms ofmRNA.
Example 14 Streptavidin immobilised on solid-phase
Streptavidin was immobilised onto porous frits by mixing the protein in 0.1 M sodium phosphate buffer with 0.01% glutaldehyde pH7 as in example 4. Biotinylated primers used to generate a PCR product were then isolated on the immobilised streptavidin. The PCR product was then made single stranded using heat or 0.1 M NaOH and used for sequencing or probe analysis.
Example 15 Use of electrodes, static charge, induction, electrophoresis to isolate DNA or RNA
Whole blood was diluted down 10 times in 1 OmM ammonium carbonate/bicarbonate, 50mM Tris. HCI with 1 % Tween 20, lOOlg/ml proteinase K pH9. Electrodes were surrounded by dialysis tubing containing the same buffer and dipped into the solution. A 12 volt direct current from a battery was connected and the nuclei or DNA was captured on the outside of the dialysis tubing at the positive electrode after a 1 hour incubation. The DNA could be removed by elution with water.

Claims

Claims
1. Equipment for extracting a material from a liquid mixture containing the material which equipment comprises a container containing a solid phase able to adsorb the material to be extracted and a reversible suction means adapted to apply suction to the solid phase to draw up the liquid mixture over the solid phase and which is able to be reversed so as to pass the liquid back over the solid phase.
2. Equipment as claimed in claim 1 which comprises a syringe and in which the solid phase is contained within the syringe below the piston so that when the nozzle of the syringe is placed in the liquid mixture and the piston is withdrawn liquid is drawn up over the solid phase and when the piston is depressed the liquid is passed back over the solid phase.
3. Equipment as claimed in claim 1 in which the container containing the solid phase is a cartridge attached to the nozzle of a syringe.
4. Equipment as claimed in claim 1 in which the reversible means comprises a pipette and there is provided a plug of the solid phase contained within the pipette.
5. Equipment as claimed in any one of claims 1 to 4 in which the solid phase comprises beads adapted to adsorb the material to be extracted.
6. Equipment as claimed in any one of claims 1 to 4 in which the solid phase comprises a plurality of spaced apart discs.
7. A method for extracting a material from a liquid mixture which method comprises applying suction so as to draw the liquid over a solid phase able to adsorb the material to be extracted and then reversing the suction to pass the liquid back over the solid phase.
8. A method as claimed in claim 7 in which the solid phase is contained within a syringe below the piston and the nozzle of the syringe is placed within the liquid and the piston withdrawn to draw the liquid over the solid phase and then the piston is depressed to pass the liquid back over the solid phase.
9. A method as claimed in claim 7 in which the nozzle of the syringe is placed in the liquid mixture and the piston is withdrawn and liquid is drawn up over the solid phase and the piston is then depressed and the liquid is passed back over the solid phase.
10. A method as claimed in claim 7 in which the reversible means comprises a pipette and there is provided a plug of the solid phase contained within the pipette.
11. A method as claimed in any one of claims 7 to 10 in which the solid phase comprises beads adapted to adsorb the material to be extracted.
12. A method as claimed in any one of claims 7 to 10 in which the solid phase comprises a plurality of spaced apart discs.
PCT/GB2000/002211 1999-06-08 2000-06-07 Sample processing device WO2000075623A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU52363/00A AU778440B2 (en) 1999-06-08 2000-06-07 Sample processing device
EP00937072A EP1183514A1 (en) 1999-06-08 2000-06-07 Sample processing device
CA002375449A CA2375449A1 (en) 1999-06-08 2000-06-07 Sample processing device
JP2001501851A JP2003501644A (en) 1999-06-08 2000-06-07 Sample processing equipment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9913275.5A GB9913275D0 (en) 1999-06-08 1999-06-08 Sample processing device
GB9913275.5 1999-06-08

Publications (1)

Publication Number Publication Date
WO2000075623A1 true WO2000075623A1 (en) 2000-12-14

Family

ID=10854928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/002211 WO2000075623A1 (en) 1999-06-08 2000-06-07 Sample processing device

Country Status (6)

Country Link
EP (1) EP1183514A1 (en)
JP (1) JP2003501644A (en)
AU (1) AU778440B2 (en)
CA (1) CA2375449A1 (en)
GB (1) GB9913275D0 (en)
WO (1) WO2000075623A1 (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096443A1 (en) * 2003-04-25 2004-11-11 november Aktiengesellschaft Gesellschaft für Molekulare Medizin Device and method for the preparation of analyte comprising liquids
EP1571437A1 (en) * 2004-02-24 2005-09-07 Hitachi High-Technologies Corporation Apparatus for isolating nucleic acid, component thereof, and method for manufacturing apparatus for isolating nucleic acid
US9146216B2 (en) * 2003-12-09 2015-09-29 Bgb Analytik Ag Device for sample preparation
EP2217344A4 (en) * 2007-10-31 2016-03-09 Akonni Biosystems Sample preparation device
CN105779277A (en) * 2015-01-13 2016-07-20 温和心 Nucleic acid extraction suction tube
CN106990193A (en) * 2017-04-28 2017-07-28 广东联捷生物科技有限公司 Solid phase extraction sample pretreating device and processing method
US10799862B2 (en) 2006-03-24 2020-10-13 Handylab, Inc. Integrated system for processing microfluidic samples, and method of using same
US10821446B1 (en) 2006-03-24 2020-11-03 Handylab, Inc. Fluorescence detector for microfluidic diagnostic system
US10844368B2 (en) 2007-07-13 2020-11-24 Handylab, Inc. Diagnostic apparatus to extract nucleic acids including a magnetic assembly and a heater assembly
US10865437B2 (en) 2003-07-31 2020-12-15 Handylab, Inc. Processing particle-containing samples
US10875022B2 (en) 2007-07-13 2020-12-29 Handylab, Inc. Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples
US10900066B2 (en) 2006-03-24 2021-01-26 Handylab, Inc. Microfluidic system for amplifying and detecting polynucleotides in parallel
US11060082B2 (en) 2007-07-13 2021-07-13 Handy Lab, Inc. Polynucleotide capture materials, and systems using same
US11142785B2 (en) 2006-03-24 2021-10-12 Handylab, Inc. Microfluidic system for amplifying and detecting polynucleotides in parallel
US11266987B2 (en) 2007-07-13 2022-03-08 Handylab, Inc. Microfluidic cartridge
US11441171B2 (en) 2004-05-03 2022-09-13 Handylab, Inc. Method for processing polynucleotide-containing samples
US11453906B2 (en) 2011-11-04 2022-09-27 Handylab, Inc. Multiplexed diagnostic detection apparatus and methods
US11549959B2 (en) 2007-07-13 2023-01-10 Handylab, Inc. Automated pipetting apparatus having a combined liquid pump and pipette head system
US11788127B2 (en) 2011-04-15 2023-10-17 Becton, Dickinson And Company Scanning real-time microfluidic thermocycler and methods for synchronized thermocycling and scanning optical detection
US11806718B2 (en) 2006-03-24 2023-11-07 Handylab, Inc. Fluorescence detector for microfluidic diagnostic system

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4699868B2 (en) * 2005-11-04 2011-06-15 株式会社日立ハイテクノロジーズ Nucleic acid purification method and nucleic acid purification instrument
JP4959450B2 (en) * 2007-07-10 2012-06-20 株式会社日立ハイテクノロジーズ Chemical analyzer
JP2014511107A (en) * 2010-12-29 2014-05-08 シーユービーアールシー コーポレイション Extraction pipette
JP5363604B2 (en) * 2012-03-21 2013-12-11 株式会社日立ハイテクノロジーズ Chemical analyzer

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0416326A2 (en) * 1989-09-06 1991-03-13 Hewlett-Packard Company Apparatus for automated isolate extraction using solid phase sorbent
WO1993001494A1 (en) * 1991-07-12 1993-01-21 Toxi Lab, Inc. Method and apparatus for improved solid phase extraction
WO1994020192A1 (en) * 1993-03-05 1994-09-15 Minnesota Mining And Manufacturing Company Method and apparatus for performing a solid-phase extraction under pressurized conditions
US5453382A (en) * 1991-08-05 1995-09-26 Indiana University Foundation Electrochromatographic preconcentration method
US5565622A (en) * 1994-09-15 1996-10-15 Hewlett-Packard Co., Legal Dept. Reduced solvent solid phase extraction
DE19516179C1 (en) * 1995-05-03 1996-11-21 Karl Prof Dr Cammann Chemical-analytical sampling device with integrated dosimeter and function display
WO1998026872A1 (en) * 1996-12-18 1998-06-25 Ansys, Inc. Method for conducting assays and separations for components of interest in fluid samples
WO1998041855A1 (en) * 1997-03-14 1998-09-24 Pawliszyn Janusz B Method and device for solid phase microextraction and desorption
WO1999013051A1 (en) * 1997-09-08 1999-03-18 Genpoint As Device for purification of organic material by adsorbing material to beads and attracting beads with magnetical, electrical or gravitational means

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0416326A2 (en) * 1989-09-06 1991-03-13 Hewlett-Packard Company Apparatus for automated isolate extraction using solid phase sorbent
WO1993001494A1 (en) * 1991-07-12 1993-01-21 Toxi Lab, Inc. Method and apparatus for improved solid phase extraction
US5453382A (en) * 1991-08-05 1995-09-26 Indiana University Foundation Electrochromatographic preconcentration method
WO1994020192A1 (en) * 1993-03-05 1994-09-15 Minnesota Mining And Manufacturing Company Method and apparatus for performing a solid-phase extraction under pressurized conditions
US5565622A (en) * 1994-09-15 1996-10-15 Hewlett-Packard Co., Legal Dept. Reduced solvent solid phase extraction
DE19516179C1 (en) * 1995-05-03 1996-11-21 Karl Prof Dr Cammann Chemical-analytical sampling device with integrated dosimeter and function display
WO1998026872A1 (en) * 1996-12-18 1998-06-25 Ansys, Inc. Method for conducting assays and separations for components of interest in fluid samples
WO1998041855A1 (en) * 1997-03-14 1998-09-24 Pawliszyn Janusz B Method and device for solid phase microextraction and desorption
WO1999013051A1 (en) * 1997-09-08 1999-03-18 Genpoint As Device for purification of organic material by adsorbing material to beads and attracting beads with magnetical, electrical or gravitational means

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096443A1 (en) * 2003-04-25 2004-11-11 november Aktiengesellschaft Gesellschaft für Molekulare Medizin Device and method for the preparation of analyte comprising liquids
US11078523B2 (en) 2003-07-31 2021-08-03 Handylab, Inc. Processing particle-containing samples
US10865437B2 (en) 2003-07-31 2020-12-15 Handylab, Inc. Processing particle-containing samples
US9146216B2 (en) * 2003-12-09 2015-09-29 Bgb Analytik Ag Device for sample preparation
EP1571437A1 (en) * 2004-02-24 2005-09-07 Hitachi High-Technologies Corporation Apparatus for isolating nucleic acid, component thereof, and method for manufacturing apparatus for isolating nucleic acid
CN100334099C (en) * 2004-02-24 2007-08-29 株式会社日立高新技术 Apparatus for isolating nucleic acid, component thereof, and method for manufacturing apparatus for isolating nucleic acid
US11441171B2 (en) 2004-05-03 2022-09-13 Handylab, Inc. Method for processing polynucleotide-containing samples
US10821446B1 (en) 2006-03-24 2020-11-03 Handylab, Inc. Fluorescence detector for microfluidic diagnostic system
US11141734B2 (en) 2006-03-24 2021-10-12 Handylab, Inc. Fluorescence detector for microfluidic diagnostic system
US10821436B2 (en) 2006-03-24 2020-11-03 Handylab, Inc. Integrated system for processing microfluidic samples, and method of using the same
US10843188B2 (en) 2006-03-24 2020-11-24 Handylab, Inc. Integrated system for processing microfluidic samples, and method of using the same
US11959126B2 (en) 2006-03-24 2024-04-16 Handylab, Inc. Microfluidic system for amplifying and detecting polynucleotides in parallel
US10857535B2 (en) 2006-03-24 2020-12-08 Handylab, Inc. Integrated system for processing microfluidic samples, and method of using same
US11806718B2 (en) 2006-03-24 2023-11-07 Handylab, Inc. Fluorescence detector for microfluidic diagnostic system
US10799862B2 (en) 2006-03-24 2020-10-13 Handylab, Inc. Integrated system for processing microfluidic samples, and method of using same
US10900066B2 (en) 2006-03-24 2021-01-26 Handylab, Inc. Microfluidic system for amplifying and detecting polynucleotides in parallel
US10913061B2 (en) 2006-03-24 2021-02-09 Handylab, Inc. Integrated system for processing microfluidic samples, and method of using the same
US11666903B2 (en) 2006-03-24 2023-06-06 Handylab, Inc. Integrated system for processing microfluidic samples, and method of using same
US11142785B2 (en) 2006-03-24 2021-10-12 Handylab, Inc. Microfluidic system for amplifying and detecting polynucleotides in parallel
US11085069B2 (en) 2006-03-24 2021-08-10 Handylab, Inc. Microfluidic system for amplifying and detecting polynucleotides in parallel
US10875022B2 (en) 2007-07-13 2020-12-29 Handylab, Inc. Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples
US11254927B2 (en) 2007-07-13 2022-02-22 Handylab, Inc. Polynucleotide capture materials, and systems using same
US11266987B2 (en) 2007-07-13 2022-03-08 Handylab, Inc. Microfluidic cartridge
US11466263B2 (en) 2007-07-13 2022-10-11 Handylab, Inc. Diagnostic apparatus to extract nucleic acids including a magnetic assembly and a heater assembly
US11549959B2 (en) 2007-07-13 2023-01-10 Handylab, Inc. Automated pipetting apparatus having a combined liquid pump and pipette head system
US11060082B2 (en) 2007-07-13 2021-07-13 Handy Lab, Inc. Polynucleotide capture materials, and systems using same
US11845081B2 (en) 2007-07-13 2023-12-19 Handylab, Inc. Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples
US10844368B2 (en) 2007-07-13 2020-11-24 Handylab, Inc. Diagnostic apparatus to extract nucleic acids including a magnetic assembly and a heater assembly
EP2217344A4 (en) * 2007-10-31 2016-03-09 Akonni Biosystems Sample preparation device
US11788127B2 (en) 2011-04-15 2023-10-17 Becton, Dickinson And Company Scanning real-time microfluidic thermocycler and methods for synchronized thermocycling and scanning optical detection
US11453906B2 (en) 2011-11-04 2022-09-27 Handylab, Inc. Multiplexed diagnostic detection apparatus and methods
CN105779277A (en) * 2015-01-13 2016-07-20 温和心 Nucleic acid extraction suction tube
CN106990193A (en) * 2017-04-28 2017-07-28 广东联捷生物科技有限公司 Solid phase extraction sample pretreating device and processing method

Also Published As

Publication number Publication date
AU5236300A (en) 2000-12-28
JP2003501644A (en) 2003-01-14
AU778440B2 (en) 2004-12-02
EP1183514A1 (en) 2002-03-06
CA2375449A1 (en) 2000-12-14
GB9913275D0 (en) 1999-08-04

Similar Documents

Publication Publication Date Title
AU778440B2 (en) Sample processing device
CN107249746B (en) Systems and methods for collecting nucleic acid samples
US9506847B2 (en) Method and system for selective isolation of target biological molecules in a general purpose system
CA2703950C (en) Apparatus, system, and method for purifying nucleic acids
AU755342B2 (en) Isolation of nucleic acids
JP3527884B2 (en) Method and apparatus for isolating and purifying nucleic acid
US20080102493A1 (en) Isolation of RNA and DNA from a biological sample
US20080153078A1 (en) System for isolating biomolecules from a sample
KR20120044918A (en) Nucleic acid purification
US20030203491A1 (en) Gravitational flow purification system
JP2018524017A (en) Apparatus and method for extracting nucleic acid
JP2008519986A (en) Instruments and methods for purification of biological materials
EP1203080B1 (en) Isolation of biomolecules
JP2006311803A (en) Method for purifying nucleic acid and tool for purifying nucleic acid
US8685742B2 (en) Apparatus and method for the more efficient isolation of nucleic acids
KR20240027088A (en) Universal Assay Cartridges and Methods of Use
RU2595374C2 (en) Method for automated extraction with simultaneous purification of nucleic acids from several biological samples
US20230383281A1 (en) Filtration methods and devices for fast nucleic acid extraction
US20030228600A1 (en) DNA isolation method and kit
JP2001299341A (en) Improved method of isolating ribonucleic acid
CA2464462A1 (en) Nucleic acid isolation method and apparatus for performing same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000937072

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2375449

Country of ref document: CA

Ref country code: CA

Ref document number: 2375449

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 52363/00

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 501851

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000937072

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09980884

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 52363/00

Country of ref document: AU